AACR21: Zen­tal­is keeps the heat on As­traZeneca with ear­ly WEE1 da­ta show­ing a group of 'ex­cep­tion­al' re­spon­ders

Long a tar­get for drug­mak­ers, the DNA dam­age re­pair path­way has picked up some new steam in re­cent years with Big Phar­ma plac­ing its bets. One of the lead­ing can­di­dates there is a WEE1 en­zyme in­hibitor from As­traZeneca, and now a small biotech play­er is look­ing to play catch up.

Zen­tal­is’ WEE1 in­hibitor, ZN-c3, post­ed par­tial re­spons­es across a slate of tu­mor types with a tol­er­a­ble safe­ty pro­file as monother­a­py for sol­id tu­mor pa­tients who are ei­ther treat­ment-re­sis­tant or have no es­tab­lished stan­dard of care, ac­cord­ing to in­ter­im Phase I da­ta pre­sent­ed as a late break­er Sat­ur­day at the vir­tu­al AACR an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER